| Literature DB >> 24929293 |
Jan Korabecny1, Rafael Dolezal2, Pavla Cabelova3, Anna Horova4, Eva Hruba3, Jan Ricny5, Lukas Sedlacek6, Eugenie Nepovimova1, Katarina Spilovska1, Martin Andrs1, Kamil Musilek7, Veronika Opletalova3, Vendula Sepsova1, Daniela Ripova5, Kamil Kuca8.
Abstract
A novel series of 7-methoxytacrine (7-MEOTA)-donepezil like compounds was synthesized and tested for their ability to inhibit electric eel acetylcholinesterase (EeAChE), human recombinant AChE (hAChE), equine serum butyrylcholinesterase (eqBChE) and human plasmatic BChE (hBChE). New hybrids consist of a 7-MEOTA unit, representing less toxic tacrine (THA) derivative, connected with analogues of N-benzylpiperazine moieties mimicking N-benzylpiperidine fragment from donepezil. 7-MEOTA-donepezil like compounds exerted mostly non-selective profile in inhibiting cholinesterases of different origin with IC50 ranging from micromolar to sub-micromolar concentration scale. Kinetic analysis confirmed mixed-type inhibition presuming that these inhibitors are capable to simultaneously bind peripheral anionic site (PAS) as well as catalytic anionic site (CAS) of AChE. Molecular modeling studies and QSAR studies were performed to rationalize studies from in vitro. Overall, 7-MEOTA-donepezil like derivatives can be considered as interesting candidates for Alzheimer's disease treatment.Entities:
Keywords: 7-MEOTA; AChE/BChE inhibitors; Alzheimer's disease; Molecular modeling; QSAR; Tacrine
Mesh:
Substances:
Year: 2014 PMID: 24929293 DOI: 10.1016/j.ejmech.2014.05.066
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514